{"slug": "health-check-blinklab-shares-surge-on-breakthrough-adhd-detection-results", "title": "Health Check: BlinkLab shares surge on breakthrough ADHD detection results", "summary": "BlinkLab (ASX:BB1) will pursue US approval of its AI-based ADHD diagnosis tool after a European study achieved 82% sensitivity and 83% specificity in children aged six to 17. The study, conducted with Mental Care Group, analyzed 208 children and supports the development of BlinkLab Dx2, a novel AI model. BlinkLab shares surged up to 15% following the announcement.", "body_md": "# Health Check: BlinkLab shares surge on breakthrough ADHD detection results\n\n**Following positive European trial results, BlinkLab is taking its ADHD program a step further****Adalta reports “highly encouraging” mesothelioma study results****Neuren sales partner ups Daybue sales guidance after record quarter**\n\n** **\n\n[ BlinkLab (ASX:BB1)](https://stockhead.com.au/company/blinklab-bb1/) will pursue US approval of its algo-based attention deficit hyperactivity disorder (ADHD) diagnosis tool, having posted positive results from a European study.\n\nCovering children aged six to 17, the study achieved sensitivity of 82% and specificity of 83%.\n\nSensitivity is the ability to detect a condition while specific is the ability to rule one out.\n\n“The study cohort represents one of the largest case-control datasets reported for ADHD assessment tools,” the company said.\n\n“The findings support development of BlinkLab Dx2, the company’s novel AI model designed to detect ADHD in addition to autism using smartphone tracking of digital neurobehavioural biomarkers.”\n\nBlinkLab will now prepare for a US study – a similar path the company took with its autism tool, unsurprisingly dubbed BlinkLab Dx1.\n\nThe company undertook the European study in collaboration with Mental Care Group (MCG), at no cost to BlinkLab.\n\nThe trial collected neurometric data from children recruited across multiple MCG centres in the Netherlands. These were supplemented by neurotypical candidates from the community (the control group).\n\nParticipants completed brief smartphone-based assessments.\n\nThese aimed to collect digital neurobehavioural biomarkers, including “subtle and involuntary” behaviours such as blinking or facial reflexes.\n\nThe study enrolled 375 kids, but this number reduced to 208 after it excluded subjects on medication or with other neurodevelopmental conditions.\n\nOf the 208 children analysed, 117 (56%) had a confirmed ADHD clinical diagnosis, while 91 (44%) had not.\n\nThe algo then identified the positive ADHD diagnosis in 82% of cases and cleared the comparison group 83% of the time.\n\n“ADHD is a significant unmet medical need and – in our view – a substantially larger addressable market than paediatric autism,” BlinkLab CEO Dr Henk-Jan Boele said.\n\nThe company notes that no blood test or brain scan currently exists for ADHD.\n\nDiagnosis depends on clinical judgements – and even two experienced clinicians can disagree.\n\n“The results provide the first evidence that digital neurobehavioural biomarkers can detect differences associated with ADHD,” BlinkLab said.\n\nIn the blink of an eye, BlinkLab shares advanced as much as 15%.\n\nThe stock has gained 70% over the last 12 months.\n\n**AdAlta’s ‘significant durability’ trial milestone**\n\n[ AdAlta (ASX:1AD)](https://stockhead.com.au/company/adalta-1ad/) reports the first patient to achieve a complete response in its advanced mesothelioma trial has passed the two-year mark without any cancer recurrence.\n\nA complete response is when a tumour completely disappears and is akin to a cure.\n\nAnother complete responder has passed the one-year survival milestone.\n\nAdAlta is trialling its acquired Car-T therapy, called EW-001 (previously BZDS-1901).\n\nThe program is under the auspices of the company’s subsidiary, AdCella, which seeks to source promising Asian therapies and commercialise them.\n\nIndeed, Shanghai Cell Therapy Group is carrying out the study, in China.\n\nOverall, the study enrolled 14 patients. The two complete responders were among 10 patients treated at higher doses.\n\n“Complete tumour clearance is almost never seen in patients with advanced mesothelioma,” AdAlta CEO Tim Oldham said.\n\n“To have achieved it in … 20% of patience is highly encouraging.”\n\nAdAlta will “continue to follow all patients in the study and report additional survival and response data as they emerge”.\n\nMeanwhile the company is preparing to meet the US Food and Drug Administration (FDA), in view of obtaining Investigational New Drug status.\n\nMesothelioma is a rare but rapidly fatal cancer of the membranes surrounding the lungs, heart and gastrointestinal organs.\n\nIt is usually associated with asbestos exposure.\n\n“Patients are typically treated initially with chemotherapy or immunotherapy,” the company said.\n\n“Once the disease has returned or progressed following these treatments, therapeutic options are limited and clinical outcomes are generally poor”.\n\nAdAlta shares climbed as much as 14% this morning.\n\n**Amplia’s lung cancer collab wins praise**\n\nBroker Bell Potter sees considerable upside for cancer drug developer [ Amplia (ASX:ATX)](https://stockhead.com.au/company/amplia-atx/) after yesterday’s announcement of non-small cell lung cancer (NSCLC) clinical collab with Big Pharma Eli Lilly.\n\nAmplia hitherto had posted outstanding complete response results with its pancreatic cancer program.\n\nAlong with ovarian cancer, NSCLC is another potential use for Amplia’s focal kinase inhibitor, narmafotinib (AMP-945).\n\nThe proposed phase Ib/IIb trial combines narmafotinib with Lilly’s Kras inhibitor, olomorasib.\n\nAmplia funds the trial, while Lilly provides its drugs and clinical expertise.\n\nBell Potter opines the tie-up confers “considerable credibility and validation for narmafotinib”, given Lilly would have undergone considerable due diligence.\n\nIt notes Lilly is “flush with cash” after divesting GLP-1 assets.\n\nThe drug combo targets 13% of cancers displaying the relevant G12C mutation, whereas only 1-2% of pancreatic cancers do so.\n\nBell Potter ascribes a speculative buy call and a 42 cents per share valuation, implying 230% of upside.\n\n**Neuren’s partner ups Daybue sales guidance**\n\n[ Neuren Pharmaceuticals’ (ASX:NEU)](https://stockhead.com.au/company/neuren-pharmaceuticals-neu/) global commercial partner Acadia Pharmaceuticals has boosted full-year sales guidance after a record June quarter for the Rett syndrome drug Daybue (trofinetide).\n\nJune (second) quarter net sales came in at US$125m, 30% higher year on year and 24% better than the March quarter.\n\nSales growth was “almost entirely” volume driven, which implies that Acadia couldn’t – or didn’t – raise prices.\n\nNeuren calls out the performance of the more convenient dosing powder formula, Daybue Stix.\n\nFor Neuren, this revenue translated to royalty income of US$12.9m, up 34% year on year.\n\nAcadia upped calendar 2026 net sales guidance to US$480-510m, from US$460-490m previously.\n\nThis implies full-year royalty income for Neuren of US$53-56m (previously US$50-54m).\n\nAcadia also reaffirmed targeted Daybue net sales of US$700m for the 2027-28 year.\n\nCurrently Acadia sells Daybue mainly in the US.\n\nBut Neuren/Acadia plan to launch Daybue in Germany by the end of the year, pending European Commission approval.\n\nThe parties also are carrying out a Japanese trial, in view of a regulatory submission there next year.\n\nOff its own bat, Neuren is conducting a phase III trial for Phelan-McDermid syndrome, dubbed Koala.\n\n**Memphasys in Pole position for baby bounce**\n\nPoland’s birth rate reportedly is less than that of even reproductive-shy Japan, but sperm sorter-outer [ Memphasys (ASX:MEM)](https://stockhead.com.au/company/memphasys-mem/) has come to the rescue.\n\nThe company has signed an exclusive commercialisation deal with Polish diagnostics distributor TK Biotech, to sell its Felix device in the country.\n\nFelix separates good sperm from dud ones, for IVF purposes.\n\nThe deal involves TK Biotech purchasing a minimum of $350,000 of product over two years.\n\nThis tie-up marks Memphasys’ third European deal, since winning CE Mark clearance for Felix last December.\n\nThe company has similar compacts in the UK and Italy.\n\nWith Poland’s birthrate well beyond the population’s replacement rate, Warsaw introduced a publicly-funded IVF program in 2024.\n\n## Related Topics\n\n### UNLOCK INSIGHTS\n\nDiscover the untold stories of emerging ASX stocks.\n\nDaily news and expert analysis, it's free to subscribe.\n\nBy proceeding, you confirm you understand that we handle personal information in accordance with our\n[Privacy Policy](https://stockhead.com.au/privacy-policy/).", "url": "https://wpnews.pro/news/health-check-blinklab-shares-surge-on-breakthrough-adhd-detection-results", "canonical_source": "https://stockhead.com.au/health/health-check-blinklab-shares-surge-on-breakthrough-adhd-detection-results/", "published_at": "2026-08-05 02:07:53+00:00", "updated_at": "2026-08-05 02:28:44.815310+00:00", "lang": "en", "topics": ["artificial-intelligence", "ai-products", "ai-research"], "entities": ["BlinkLab", "Mental Care Group", "Henk-Jan Boele", "AdAlta", "Tim Oldham", "Shanghai Cell Therapy Group"], "alternates": {"html": "https://wpnews.pro/news/health-check-blinklab-shares-surge-on-breakthrough-adhd-detection-results", "markdown": "https://wpnews.pro/news/health-check-blinklab-shares-surge-on-breakthrough-adhd-detection-results.md", "text": "https://wpnews.pro/news/health-check-blinklab-shares-surge-on-breakthrough-adhd-detection-results.txt", "jsonld": "https://wpnews.pro/news/health-check-blinklab-shares-surge-on-breakthrough-adhd-detection-results.jsonld"}}